CN103143064A - Magnetic polycaprolactone tissue engineering scaffold - Google Patents
Magnetic polycaprolactone tissue engineering scaffold Download PDFInfo
- Publication number
- CN103143064A CN103143064A CN2013100463776A CN201310046377A CN103143064A CN 103143064 A CN103143064 A CN 103143064A CN 2013100463776 A CN2013100463776 A CN 2013100463776A CN 201310046377 A CN201310046377 A CN 201310046377A CN 103143064 A CN103143064 A CN 103143064A
- Authority
- CN
- China
- Prior art keywords
- magnetic
- polycaprolactone
- tissue engineering
- engineering bracket
- leaching
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention relates to a magnetic polycaprolactone tissue engineering scaffold, and is a porous material with Fe3O4 contained in polycaprolactone. The mass content of Fe3O4 is 0.1-80%. The particle size of the Fe3O4 is 1-107nm, the porosity is 0.01-99.9%, and the pore size is 1-107nm. With the invention, the tedious steps of a magnetic targeted drug delivery process can be reduced, and the toxic effects of drugs on the whole body can be avoided. Also, the magnetic polycaprolactone tissue engineering scaffold can be used for other magnetic-targeted treatment means.
Description
Technical field
The present invention relates to a kind of magnetic polycaprolactone tissue engineering bracket.
Background technology
The primary and foremost purpose of tissue engineering technique development be applied to clinical, with treatment because tissue loss or disease that the organ failure was produced.Traditional Therapeutic Method comprises organ transplantation, surgical reconstruction, use machinery and regular injection of medicine etc., and these methods are not only expensive but also usually can not effectively reach therapeutic purposes.
Along with the development of life sciences and physics, chemistry, material subject, tissue engineering is arisen at the historic moment, and this has just fundamentally solved dysfunction due to tissue and organ defect or the treatment problem of forfeiture.Its basic skills is the high concentration histiocyte with In vitro culture, be adsorbed in after amplification a kind of biocompatibility good, and can be by human body progressively on the extracellular matrix of degraded and absorbed.This material can be the three dimensions that cell provides existence, is conducive to cell and obtains enough nutrient substance, carries out gas exchange, gets rid of waste material, makes cell by the three-dimensional rack growth of prefabricated form.Then with this cell biological composite body implanting to human body disease damage position, at biological support progressively in the degraded and absorbed process, the cell of plantation continues the hypertrophy breeding, has formed new respective organization and organ with its original specific function and form, reaches the purpose of repairing wound and Reconstruction of The Function.
Tissue engineering bracket is the engineered the most basic framework of organizing, and it not only provides the support structure effect for specific cell, but also plays template action, guide tissue regeneration and control organizational structure.Polycaprolactone degradable, nontoxic, easy processing are the tissue engineering bracket materials of commonly using.
The magnetic target drug-supplying system reduces medicine to the toxic action of whole body owing to can treating more targetedly disease, and becomes the focus of research.But the driving force that traditional magnetic target drug-supplying system externally-applied magnetic field commonly used is assembled as medicine makes the administration process steps loaded down with trivial details.
Summary of the invention
The purpose of this invention is to provide a kind of when exercising cell, tissue construction cradling function, the magnetic magnetic polycaprolactone tissue engineering bracket that can be used for magnetic target drug-supplying system targeting of tool.
The present invention is with Fe
3O
4Add the polycaprolactone tissue engineering bracket, the magnetic tissue engineering bracket that can be used for magnetic target drug-supplying system targeting of preparation tool.For containing Fe in polycaprolactone
3O
4The porous material of powder.
Adopt suitable processing method preparation to contain Fe
3O
4Magnetic polycaprolactone tissue engineering bracket.
Described suitable processing method, comprise solvent cast-granule leaching, film material lamination, fiber combination, melt molding, extrude leaching, emulsion lyophilization, heat bring out be separated, supercritical fluid technology, supercritical liq-leaching, 3 D-printing (leaching) and melt extrude the methods such as molding.
Described Fe
3O
4Refer to that particle diameter is at 1-10
7Fe between nm
3O
4
Described magnetic polycaprolactone tissue engineering bracket refers to porosity 0.01-99.9%, aperture 1-10
7Nm, Fe
3O
4The polycaprolactone tissue engineering bracket of mass content 0.1-80%.
Beneficial effect of the present invention:
(1) reduce medicine to the toxic action of whole body.
(2) the deperm loaded down with trivial details step of target administration process.
(3) also can be used for other with the treatment means of magnetic as targeting.
Description of drawings
Fig. 1 is the stereoscan photograph of polycaprolactone magnetic tissue engineering bracket; Polycaprolactone and Fe
3O
4It is 1:0 that the powder quality ratio is respectively E0; E1 is 0.95:0.05; E2 is 0.9:0.1; E3 is 0.8:0.2; E4 is 0.4:0.6;
Fig. 2 be with the compatibility of mouse marrow stem cell induced osteogenesis cell detection material (take without the culture fluid of any processing as control group);
Fig. 3 fluorescence microscope photo;
Fig. 4 H﹠amp; The E picture that dyes.
The specific embodiment
Further illustrate the present invention below in conjunction with embodiment, but these embodiment are not meant to and limit the scope of the invention.
Embodiment 1
The 1g polycaprolactone is dissolved in appropriate oxolane, with the Fe of 0.10g particle diameter less than 50nm
3O
4Powder and 9g particle diameter are to add in the polycaprolactone solution of abundant dissolving after the NaCl mix homogeneously of 200-300 micron, stir, and pour mould into.Allow solvent fully naturally volatilize, after the dry 6h of normal-temperature vacuum, add the abundant leaching of distilled water, make porogen NaCl stripping, make and contain Fe
3O
4Polycaprolactone magnetic tissue engineering bracket.
Embodiment 2
The 3g polycaprolactone is dissolved in the 30ml oxolane, with the Fe of 0.5g particle diameter less than 5 microns
3O
4Powder adds in the polycaprolactone solution of abundant dissolving, stirs, and after liquid nitrogen flash freezer, puts into vacuum freeze drier, makes solvent fully volatilize, and makes and contains Fe
3O
4Polycaprolactone magnetic tissue engineering bracket.
Embodiment 3
500g polycaprolactone, 100g particle diameter are less than the Fe of 50 microns
3O
4Powder and 800g particle diameter are to add screw extruder, 70 ℃ of extrusion moldings after the NaCl granule mix homogeneously of 300400 microns.After cooling, add distilled water fully to soak material, make porogen NaCl stripping, make and contain Fe
3O
4Polycaprolactone magnetic tissue engineering bracket.
Embodiment 4
Polycaprolactone is dissolved in appropriate oxolane, with the Fe of appropriate particle diameter less than 5 microns
3O
4Powder (polycaprolactone and Fe
3O
4It is 1:0 that the powder quality ratio is respectively E0; E1 is 0.95:0.05; E2 is 0.9:0.1; E3 is 0.8:0.2; E4 is 0.4:0.6) and particle diameter be that 355-500 micron quality is polycaprolactone and Fe
3O
4Add in the polycaprolactone solution of abundant dissolving after the NaCl mix homogeneously of 9 times of powder quality, stir, pour mould into.After allowing solvent fully naturally volatilize 7 days, add the abundant leaching of distilled water, make porogen NaCl stripping, make and contain 0%(E0), 5%(E1), 10%(E2), 20%(E3) and 40%(E4) Fe
3O
4Polycaprolactone magnetic tissue engineering bracket.
Fig. 1 is the stereoscan photograph of polycaprolactone magnetic tissue engineering bracket.
Fig. 2 be with the compatibility of mouse marrow stem cell induced osteogenesis cell detection material (take without the culture fluid of any processing as control group): cell and material are cultivated altogether, its active and cytoactive without the fresh medium of any processing compares, and result shows that polycaprolactone magnetic tissue engineering bracket has good cell compatibility.
E3 is implanted mouse back, injected fluorescently-labeled magnetic suspension liquid at abdominal part on the 2nd day, killed mice on the 5th day, the taking-up material is made frozen section and can be seen under fluorescence microscope: (Fig. 3 a) to assemble a large amount of fluorescence on material; The blood smear only has the fluorescence (Fig. 3 b) of minute quantity.This explanation polycaprolactone magnetic tissue engineering bracket has very high capture rate to magnetisable material, can be used as the magnetic target of magnetic target drug-supplying system.
Simultaneously the frozen section of embedded material is H﹠amp; E dyeing although can see only having shortly 5 days, has had a large amount of tissues to implant polycaprolactone magnetic tissue engineering brackets inner (Fig. 4), illustrates that polycaprolactone magnetic tissue engineering bracket has good biocompatibility.
Claims (4)
1. magnetic polycaprolactone tissue engineering bracket, it is for containing Fe in polycaprolactone
3O
4Porous material.
2. a kind of magnetic polycaprolactone tissue engineering bracket according to claim 1, is characterized in that described Fe
3O
4Mass content is at 0.1-80%.
3. a kind of magnetic polycaprolactone tissue engineering bracket according to claim 1, is characterized in that described Fe
3O
4Particle diameter is at 1-10
7Between nm, described porosity is 0.01-99.9%, aperture 1-10
7Nm.
4. the preparation method of a kind of magnetic polycaprolactone tissue engineering bracket claimed in claim 1, adopt solvent cast-granule leaching, film material lamination, fiber combination, melt molding, extrude leaching, emulsion lyophilization, heat bring out be separated, supercritical fluid technology, supercritical liq-leaching, 3 D-printing or melt extrude molding methods.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100463776A CN103143064A (en) | 2013-02-05 | 2013-02-05 | Magnetic polycaprolactone tissue engineering scaffold |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100463776A CN103143064A (en) | 2013-02-05 | 2013-02-05 | Magnetic polycaprolactone tissue engineering scaffold |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103143064A true CN103143064A (en) | 2013-06-12 |
Family
ID=48541562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100463776A Pending CN103143064A (en) | 2013-02-05 | 2013-02-05 | Magnetic polycaprolactone tissue engineering scaffold |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103143064A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104200948A (en) * | 2014-08-26 | 2014-12-10 | 太仓碧奇新材料研发有限公司 | Nanocrystalline iron oxide-based magnetic material for 3D printing and preparing method thereof |
| CN106474555A (en) * | 2016-11-04 | 2017-03-08 | 暨南大学 | A kind of polycaprolactone of 3D printing/oyster shell powder composite and preparation and application and the bone tissue engineering scaffold based on which |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1951498A (en) * | 2006-08-07 | 2007-04-25 | 中国科学院广州化学研究所 | A fibroid magnetic medicament and preparation method thereof |
| WO2011075516A2 (en) * | 2009-12-18 | 2011-06-23 | President And Fellows Of Harvard College | Active scaffolds for on-demand drug and cell delivery |
| CN102885783A (en) * | 2012-09-26 | 2013-01-23 | 复旦大学附属金山医院 | Nanometer medicament microspheres |
-
2013
- 2013-02-05 CN CN2013100463776A patent/CN103143064A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1951498A (en) * | 2006-08-07 | 2007-04-25 | 中国科学院广州化学研究所 | A fibroid magnetic medicament and preparation method thereof |
| WO2011075516A2 (en) * | 2009-12-18 | 2011-06-23 | President And Fellows Of Harvard College | Active scaffolds for on-demand drug and cell delivery |
| CN102885783A (en) * | 2012-09-26 | 2013-01-23 | 复旦大学附属金山医院 | Nanometer medicament microspheres |
Non-Patent Citations (5)
| Title |
|---|
| J. YANG ETAL.: ""Preparation of poly ε-caprolactone nanoparticles containing magnetite for magnetic drug carrier"", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 * |
| KYUNG-YON KIM ETAL.: ""Characterization and Preparation of PCL encapsulated Fe3O4 nanoparticle for targeted drug delivery system(Ⅱ)"", 《THEORIES AND APPLICATIONS OF CHEMICAL ENGINEERING》 * |
| 侯鹏: ""磁性纳米复合生物材料的制备及表征"", 《中国优秀硕士毕业论文 医药卫生科技辑》 * |
| 李愔喆: ""三维有序壳聚糖多孔支架的研究"", 《中国优秀硕士毕业论文 医药卫生科技辑》 * |
| 苏佳灿 等: ""纳米羟基磷灰石/聚己内酯复合生物活性多孔支架研究"", 《无机材料学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104200948A (en) * | 2014-08-26 | 2014-12-10 | 太仓碧奇新材料研发有限公司 | Nanocrystalline iron oxide-based magnetic material for 3D printing and preparing method thereof |
| CN106474555A (en) * | 2016-11-04 | 2017-03-08 | 暨南大学 | A kind of polycaprolactone of 3D printing/oyster shell powder composite and preparation and application and the bone tissue engineering scaffold based on which |
| CN106474555B (en) * | 2016-11-04 | 2019-09-17 | 暨南大学 | A kind of polycaprolactone of 3D printing/oyster shell powder composite material and preparation and application and the bone tissue engineering scaffold based on it |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qazi et al. | Biomaterials based strategies for skeletal muscle tissue engineering: existing technologies and future trends | |
| US11903976B2 (en) | Implantable therapeutic delivery system having a nanofibrous core | |
| Wang et al. | Responsive graphene oxide hydrogel microcarriers for controllable cell capture and release | |
| CN101282652A (en) | Prevascularized devices and related methods | |
| US20140024760A1 (en) | Three-dimensional nanofiber scaffold for tissue repair and preparation method thereof | |
| CN103990182A (en) | Three-dimensional scaffold material for bone tissue repair and preparation method thereof | |
| US20140017304A1 (en) | Method for encapsulated therapeutic products and uses thereof | |
| KR102102153B1 (en) | A bead for cell encapsulation and culture based on decellularized tissue, and use thereof | |
| CN102836016A (en) | Implanting type degradable device for promoting nerve regeneration after ambient nerve implanting | |
| CN102505184A (en) | Tissue engineering fiber bundle structure body and preparation method thereof | |
| CN101850136A (en) | Implantable bioartificial liver | |
| DE112017005025T5 (en) | Compositions containing adjustable concentrations of growth factors from blood serum and clot hypoxia-conditioned medium and process for their preparation | |
| CN105251052A (en) | Cartilage extracellular matrix and silk fibroin composite orientation cartilage support and preparation method thereof | |
| EP3821919B1 (en) | Method for producing a bioartificial primarily acellular fibrin-based construct and the construct itself | |
| JP6955007B2 (en) | Two-part implantable therapeutic delivery device | |
| CN104483178A (en) | Preparation method of chromosomes of adult epinephelus akaara | |
| EP1083984A1 (en) | Method for populating substrates with biological cells and populating devices that can be used therefor | |
| CN101716372A (en) | Method for preparing tissue engineering scaffold by pore forming of directional soluble fibres | |
| CN103143064A (en) | Magnetic polycaprolactone tissue engineering scaffold | |
| Augustine et al. | Oxygen-generating scaffolds: One step closer to the clinical translation of tissue engineered products | |
| KR20200010344A (en) | Yarn and its manufacturing method | |
| CN105126171A (en) | Gel biological material having shape memory function and preparation method of gel biological material | |
| CN106552286A (en) | The preparation method of artificial cartilage | |
| CN105343937A (en) | Composite porous sponge material and preparation method thereof | |
| CN102631710A (en) | Preparation method of precursor of composite tissues and organs with multichannel multilayer cell structure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130612 |